Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Wegener's granulomatosis and microscopic polyangiitis are antineutrophil cytoplasm antibodies (ANCA)-associated vasculitides with significant morbidity and mortality. The long-term survival of patients with ANCA associated vasculitis treated with current regimens is uncertain. OBJECTIVE: To describe the long-term patient survival and possible prognostic factors at presentation in an international, multicentre, prospectively recruited representative patient cohort who were treated according to strictly defined protocols at presentation and included the full spectrum of ANCA-associated vasculitis disease. METHODS: Outcome data were collected for 535 patients who had been recruited at the time of diagnosis to four randomised controlled trials between 1995 and 2002. Trial eligibility was defined by disease severity and extent, covered the spectrum of severity of ANCA-associated vasculitis and used consistent diagnostic criteria. Demographic, clinical and laboratory parameters at trial entry were tested as potential prognostic factors in multivariable models. RESULTS: The median duration of follow-up was 5.2 years and 133 (25%) deaths were recorded. Compared with an age- and sex-matched general population there was a mortality ratio of 2.6 (95% CI 2.2 to 3.1). Main causes of death within the first year were infection (48%) and active vasculitis (19%). After the first year the major causes of death were cardiovascular disease (26%), malignancy (22%) and infection (20%). Multivariable analysis showed an estimated glomerular filtration rate <15 ml/min, advancing age, higher Birmingham Vasculitis Activity Score, lower haemoglobin and higher white cell count were significant negative prognostic factors for patient survival. CONCLUSION: Patients with ANCA-associated vasculitis treated with conventional regimens are at increased risk of death compared with an age- and sex-matched population.

Original publication

DOI

10.1136/ard.2010.137778

Type

Journal article

Journal

Annals of the rheumatic diseases

Publication Date

03/2011

Volume

70

Pages

488 - 494

Addresses

Royal Berkshire Hospital, Renal Unit, London Road, Reading, Berkshire RG1 5AN, UK. oflossmann@doctors.org.uk

Keywords

European Vasculitis Study Group, Humans, Immunosuppressive Agents, Glomerular Filtration Rate, Prognosis, Treatment Outcome, Remission Induction, Epidemiologic Methods, Age Distribution, Adult, Aged, Middle Aged, Female, Male, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis